Construction MaterialsLarge capRs 103,003 crRs 111.9 cr traded a dayInfrastructureCommoditiesMultinationals
Close on 2026-08-21
414.50
+0.85%
52-week range10% of the way up
395.35591.60
Market cap
103,003 cr
P/E (TTM)
19.9×
industry 30×
EPS (TTM)
20.87
Revenue YoY
-7.7%
Q1 FY27
Profit YoY
-31.9%
Net margin
6.9%
-2.5pt vs a year ago
Growth trend
-18.1pt
vs last quarter’s YoY
1 month
-2.1%
Below 52w high
42.7%
RSI (14)
26
oversold
Daily swing
2.0%
average true range
Volume
1.8×
vs 20-day average
Traded
Rs 112 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−0.72%
1 month
−2.14%
3 months
−7.83%
6 months
−19.07%
1 year
−26.93%
The read
written from the numbers on this page
The evidence is mixed4 supporting, 5 against, 1 worth knowing
Supporting
matches trading far more than usual, which has beaten the market by +0.45 points over 20 sessions across 52,251 past signals
2 of the scans it matches have a positive measured record
priced at 20× earnings against an industry median of 30× — 33% below its peers
futures show a long buildup — the move is being funded by new positions
Against
trading 12% below its 200-day average
at 10% of its 52-week range — nearly everyone who bought in the past year is underwater
down 27% over twelve months
revenue fell 8% year on year in the quarter ending 2026-06-30
net margin has narrowed from 25.1% to 6.9% across four quarters
Worth knowing
RSI at 26 is washed out — historically the better half of this site's measured edge comes from exactly this condition
AMBUJACEM sits in Infrastructure, Commodities, Multinationals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close back above 474, its 200-day average; open interest reversing while price keeps going.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working
Nothing in the filings stands out either way.
Needs watching3
Net profit -31.9% year on year, Rs 970 cr to Rs 660 cr.
-31.9%Rs 970 crRs 660 cr
Profit grew slower than revenue, -31.9% against -7.7%.
-31.9%-7.7%
Net margin moved from 9.4% to 6.9%.
9.4%6.9%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
2 of 47 matched on 2026-08-21
AMBUJACEM matches 2 of the 47 scans today, across 2 different kinds of evidence.
AMBUJACEM trades at 20× trailing earnings, below its median of 26× over this window — 23% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Credit rating filings were typically +0.58pt vs the market over the next 5 sessions (n=266) · Capacity / capex filings were typically +0.51pt vs the market over the next 5 sessions (n=55)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
nothing clear in the filed numbers
Going against it
revenue fell 8% against the same quarter a year earlier
profit dropped 32% year on year
net margin narrowed from 17.0% to 6.9%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
9,500
843
660
2.32
6.9%
Q4 FY26
2026-03-31 · consolidated
10,915
522
1,857
7.41
17.0%
Q3 FY26
2025-12-31 · consolidated
10,277
407
367
0.82
3.6%
Q2 FY26
2025-09-30 · consolidated
9,174
833
2,302
7.15
25.1%
Q1 FY26
2025-06-30 · consolidated
10,289
1,328
970
3.20
9.4%
Q4 FY25
2025-03-31 · consolidated
9,889
1,775
1,282
3.88
13.0%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-3.2%
Versus 200-day average-12.5%
Below 52-week high-29.9%
Above 52-week low+4.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)26.0
Higher closes in last 52 of 5
Six-month return−19.07%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.02%
Volume versus 20-day1.8x
Median daily turnoverRs 111.9 cr
Derivatives
near expiry 2026-08-25 · 2026-08-20
Long Buildup
Price up, open interest up. New buyers are arriving rather than old sellers leaving — the move is being funded, not squeezed.
Futures basis versus spot+0.34%
Open interest change+1.5%
Put / call ratio0.50
Put wall (support)500
Call wall (resistance)430
Max pain430
How to read this
Open interest is contracts still open, so a rise means new positions and a fall means positions closing. Combined with price direction that gives the state on the left. The walls are the strikes carrying the most open interest near expiry — levels other people are watching, not levels the price is obliged to respect. A future below spot means sellers are paying to be short.
Peers
Construction Materials · 16 classified companies
AMBUJACEM trades at 19.9× trailing earnings against an industry median of 29.8× across 15 other classified companies in its industry — cheaper than them, by 33%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.